A. Cunningham

Defining the landscape of human epidermal mononuclear phagocytes.
202315 citationsauthor #5
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
20233 citationsauthor #3
Interferon inhibits the release of herpes simplex virus-1 from the axons of sensory neurons
202311 citationsauthor #7
Reanalysis of single-cell RNA sequencing data does not support herpes simplex virus 1 latency in non-neuronal ganglionic cells in mice
20233 citationsauthor #3
Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
202331 citationsauthor #47
Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity
20233 citationsauthor #14
An Analysis of How Herpes Zoster Pain Affects Health-related Quality of Life of Placebo Patients From 3 Randomized Phase III Studies
20235 citationsauthor #6
REPRINTED WITH PERMISSION OF IASP PAIN 164 (2023) 741748: Adjuvanted recombinant zoster vaccine decreases herpeszoster-associated pain and the use of pain medicationacross 3 randomized, placebo-controlled trials
20230 citationsauthor #4
Redefining the human corneal immune compartment using dynamic intravital imaging
202346 citationsauthor #9
Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D
20229 citationsauthor #6
An in situ analysis pipeline for initial host-pathogen interactions reveals signatures of human colorectal HIV transmission.
20228 citationsauthor #21
SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity
202234 citationsauthor #30
The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells
202261 citationsauthor #16
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
202286 citationsauthor #33
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
202234 citationsauthor #17
Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
202218 citationsauthor #5
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
202212 citationsauthor #4
Herpes simplex virus-1 utilizes the host actin cytoskeleton for its release from axonal growth cones
202210 citationsauthor #5
An in situ quantitative map of initial human colorectal HIV transmission
20220 citationsauthor #21
Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials
20228 citationsauthor #5
SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity
20220 citationsauthor #30
Tissue resident memory T cells inhabit the deep human conjunctiva
20229 citationsauthor #4
HIV transmitting mononuclear phagocytes; integrating the old and new
202222 citationsauthor #6
Cytokines and chemokines: The vital role they play in herpes simplex virus mucosal immunology
202229 citationsauthor #4
The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
202113 citationsauthor #19
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
202189 citationsauthor #41
23. ZOE-50 and ZOE-70 Placebo Groups Data Shows that Burden of Pain Associated with Herpes Zoster Interferes with Activities of Daily Living
20210 citationsauthor #6
A putative WAVE regulatory complex (WRC) interacting receptor sequence (WIRS) in the cytoplasmic tail of HSV-1 gE does not function in WRC recruitment or neuronal transport
20210 citationsauthor #4
Vaccines for older adults
202138 citationsauthor #1
Human anogenital monocyte-derived dendritic cells and langerin+cDC2 are major HIV target cells
202143 citationsauthor #27
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity
202140 citationsauthor #16
Herpes Simplex Virus type 1 infects Langerhans cells and the novel epidermal dendritic cell, Epi-cDC2s, via different entry pathways
202126 citationsauthor #17
Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue
20218 citationsauthor #15
Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine
202113 citationsauthor #7
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
202152 citationsauthor #2
26. Is There a Correlation Between Reactogenicity and Immune Responses of the Adjuvanted Recombinant Zoster Vaccine (RZV)? A Post-hoc Analysis
20210 citationsauthor #8
A NOVEL LANGERIN EXPRESSING TYPE 2-CONVENTIONAL DENDRITIC CELL IS SIGNIFICANTLY DECREASED IN CROHN’S DISEASE
20210 citationsauthor #4
Plasmacytoid dendritic cells have divergent effects on HIV infection of initial target cells and induce a pro-retention phenotype
202110 citationsauthor #17
Herpes Simplex Virus Type 1 Interactions with the Interferon System
202074 citationsauthor #3
7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
20200 citationsauthor #4
The Use of Microfluidic Neuronal Devices to Study the Anterograde Axonal Transport of Herpes Simplex Virus-1.
20203 citationsauthor #2
The Role of Tissue Resident Memory CD4 T Cells in Herpes Simplex Viral and HIV Infection
202023 citationsauthor #6
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials
202020 citationsauthor #11
Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
202048 citationsauthor #9
Identification of HIV-Transmitting Sub-Epithelial Mononuclear Phagocytes in Human Anogenital and Colorectal Tissues
20201 citationsauthor #25
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity
202057 citationsauthor #9
Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine
202021 citationsauthor #9
Transmission Immunoelectron Microscopy of Herpes Simplex Virus-1-Infected Dorsal Root Ganglia Neurons Sectioned in Growth Plane.
20201 citationsauthor #3
Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
202015 citationsauthor #5
Identification of HIV transmitting CD11c+ human epidermal dendritic cells
201985 citationsauthor #30
2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1
20191 citationsauthor #11
Persistence of a T Cell Infiltrate in Human Ganglia Years After Herpes Zoster and During Post-herpetic Neuralgia
20199 citationsauthor #5
List of Contributors
20190 citationsauthor #7
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.
201927 citationsauthor #3
Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design
201936 citationsauthor #4
Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
201946 citationsauthor #23
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
201954 citationsauthor #22
Preparation of Herpes Simplex Virus-Infected Primary Neurons for Transmission Electron Microscopy.
20191 citationsauthor #3
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.
201991 citationsauthor #2
Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares
20194 citationsauthor #3
2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis
20190 citationsauthor #9
Herpes zoster: improving protection in older people
20192 citationsauthor #2
AFid: A tool for automated identification and exclusion of autofluorescent objects from microscopy images
201912 citationsauthor #5
Manipulation of Mononuclear Phagocytes by HIV: Implications for Early Transmission Events
201916 citationsauthor #6
Mass Cytometry Imaging for the Study of Human Diseases—Applications and Data Analysis Strategies
2019150 citationsauthor #3
Cytoskeletons in the Closet—Subversion in Alphaherpesvirus Infections
201824 citationsauthor #3
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
201840 citationsauthor #3
Efficacy, Immunogenicity and Safety of adjuvanted Herpes Zoster-Virus Subunit Vaccine Candidates in Adults from 60 Years and older : Results from the Efficacy Studies ZOE-50 and ZOE-70
20180 citationsauthor #3
From Ocean to Bedside: the Therapeutic Potential of Molluscan Hemocyanins.
201810 citationsauthor #4
Antimicrobial Peptides of Marine Crustaceans: The Potential and Challenges of Developing Therapeutic Agents.
201828 citationsauthor #3
Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
2018166 citationsauthor #1
Herpes Zoster Vaccines
201863 citationsauthor #1
Infection and Transport of Herpes Simplex Virus Type 1 in Neurons: Role of the Cytoskeleton
2018102 citationsauthor #4
Murine skin-resident γδT cells impair the immune response to HSV in skin.
20183 citationsauthor #9
Vaccine profile of herpes zoster (HZ/su) subunit vaccine
201730 citationsauthor #1
Phenotypic and functional consequences of different isolation protocols on skin mononuclear phagocytes
201750 citationsauthor #16
Dendritic cells in the cornea during Herpes simplex viral infection and inflammation.
201726 citationsauthor #7
Zinc is a potent and specific inhibitor of IFN-λ3 signalling
201753 citationsauthor #7
Langerhans cells and sexual transmission of HIV and HSV
201731 citationsauthor #7
Mechanism of Interferon-Stimulated Gene Induction in HIV-1-Infected Macrophages
201751 citationsauthor #13
Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies
20166 citationsauthor #3
Vaccine provision: Delivering sustained & widespread use.
201637 citationsauthor #3
The herpes zoster subunit vaccine
201640 citationsauthor #1
Comparison of Haliotis rubra hemocyanin isoforms 1 and 2
20166 citationsauthor #2
Vaccination of special populations: Protecting the vulnerable.
2016180 citationsauthor #7
HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF-κB
201629 citationsauthor #14
Fast track, dynein-dependent nuclear targeting of human immunodeficiency virus Vpr protein; impaired trafficking in a clinical isolate.
20168 citationsauthor #5
HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF-κB
20166 citationsauthor #14
Vaccine development: From concept to early clinical testing.
2016105 citationsauthor #1
Understanding natural herpes simplex virus immunity to inform next-generation vaccine design
201614 citationsauthor #3
Why Australia needs a Medical Research Future Fund.
20151 citationsauthor #1
Reactogenicity of an adjuvanted herpes zoster subunit vaccine in older adults: results of the phase 3 ZOE-50 trial
20150 citationsauthor #2
Faculty Opinions recommendation of Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.
20150 citationsauthor #1
Increasing Trends of Herpes Zoster in Australia
201553 citationsauthor #6
Relay of Herpes Simplex Virus between Langerhans Cells and Dermal Dendritic Cells in Human Skin
201566 citationsauthor #13
HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1
201592 citationsauthor #13
The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from Neurons
201553 citationsauthor #10
Abalone Hemocyanin Blocks the Entry of Herpes Simplex Virus 1 into Cells: a Potential New Antiviral Strategy
201538 citationsauthor #9
Dendritic Cells Produce TNF-Infected − Herpes Simplex Virus Type 2
20150 citationsauthor #9
The C-type Lectin Langerin Functions as a Receptor for Attachment and Infectious Entry of Inﬂuenza A Virus
20151 citationsauthor #4

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT